FAQs


What is HER-2/neu?
HER-2/neu, also known as c-erbB2, is a gene that plays a key role in the regulation of cell growth. The HER-2 gene is amplified in human breast, ovarian, and other cancers, and plays an important role in the progression of many tumors. This amplification is characterized by increased transcription of mRNA and subsequent overexpression of the gene product. Approximately 20-25% of breast cancers have amplification of the HER-2 gene. Detection of HER-2 amplification is important in the diagnosis, prognosis, selection of appropriate therapy and prediction of therapeutic outcome in certain cancers.4

back to top

How important is HER-2 amplification in the treatment of breast cancer?
HER-2 amplification and subsequent overexpression of the gene product have emerged as a key prognostic and therapeutic marker in breast cancer. Amplification of this gene is found to be associated with rapid proliferation, shorter disease-free survival and poorer overall survival in both node-negative and node-positive ductal breast cancers. With the advent of monoclonal targeted therapies such as Herceptin® ® (Trastuzumab), accurate HER-2 assessment can be a critical component in determining appropriate therapy selection. Both the National Comprehensive Cancer Network (NCCN®) and the American Society of Clinical Oncology (ASCO®) recommend HER-2 assessment for all invasive breast cancers.

back to top

What is the connection between HER-2 status and the selection of adriamycin-based therapy?
An interaction between HER-2 amplification and response to adriamycin-based therapies has been demonstrated. Specifically, HER-2 amplification is associated with improved response to intensified adriamycin-based chemotherapies. Clinical trials demonstrate that patients with HER-2 amplification may benefit from dose intensive adriamycin-based therapy based on disease-free and overall survival. Dose intensification of adriamycin did not benefit women without HER-2 amplification.5

back to top

What is the connection between HER-2 status and Herceptin® therapy selection?
The Herceptin® package insert states that detection of HER-2 status is necessary for selection of patients appropriate for Herceptin therapy. Herceptin package insert data from a retrospective analysis of 660 patients enrolled in the clinical studies (all scoring 2+ or 3+ by the Clinical Trial IHC assay) demonstrate that the clinical benefits of Herceptin were greater in patients whose tumors tested FISH(+) than FISH( -). In the single-arm study of Herceptin as a single agent, the overall response rate in patients whose tumors tested as FISH(+) was 20%, while there was no response in those patients who tested as FISH( -). For more information on HER-2 testing and Herceptin, visit www.Herceptin.com.

back to top

Why is accurate assessment of HER-2 status valuable?
HER-2 status is a strong, independent predictor of prognosis and disease free progression. Accurate assessment of HER-2 status can be a powerful tool along with existing clinical and pathologic information to assist in predicting prognosis and disease-free progression in selecting appropriate therapy, including Herceptin therapy.

The risks of incorrect HER-2 status assessment are significant: false positive assessments may lead to inappropriate medical decisions, causing a patient to undergo unnecessary therapy. Conversely, a false negative assessment may deprive a patient of potentially beneficial therapy.

back to top

Should one be assessing HER-2 at the DNA level or the gene product (protein) level?
Extra copies of the HER-2 gene drive excess protein on the surface of the cell. HER-2 assessment at a direct molecular level by FISH has been shown to be more accurate than IHC antibody-based tests.1 Responses in IHC 2+ and 3+ MBC patients treated with single-agent Herceptin were seen exclusively in FISH positive patients2.

back to top

What are the most accurate methods available for HER-2 status assessment?
Tests for HER-2 status measure either gene copy number or presence of protein receptors. The two most widely used technologies and the only two approved by the FDA in the United States are Immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH). Chromogenic in situ Hybridization (CISH) and Silver in situ Hybridization (SISH) are two other technologies that measure HER-2 gene copy number. All of these techniques are routinely utilized on formalin-fixed, paraffin-embedded breast tissue.

While IHC has been a widely used technique, questions have been raised as to which technique, either FISH or IHC, yields the most reliable and accurate detection of HER-2 status. From the clinical pathology perspective, IHC inherently possesses several key shortcomings that can interfere with the accurate assessment of HER-2 status. Formalin-fixation of tissues is important in stabilizing cellular morphology and it introduces variables for IHC determination that are not within the laboratory's power to control. Specifically, formalin-fixation can cause destruction of the HER-2 epitope, which can lead to false negative IHC results. To help minimize this shortcoming, antigen retrieval techniques have now been employed. However, these antigen retrieval techniques cause a significant number of false positive IHC results.

Direct FISH technology targets stable DNA at a molecular level within formalin-fixed, paraffin-embedded specimens thereby overcoming the misclassifications associated with IHC. Direct FISH is a very sensitive method that yields highly accurate, reliable and reproducible results simply from counting the number of fluorescent signals. From these results, the pathologist can make HER-2 assessments with a high degree of accuracy which can help lead oncologists and patients to the most efficacious selection of therapy.

back to top

What is the PathVysion HER-2 DNA Probe Kit?
The PathVysion HER-2 DNA Probe Kit utilizes patented, direct labeled Fluorescent in situ Hybridization DNA probes to yield reliable results at the molecular level. FISH is a molecular genetic technique employing a fluorescent DNA probe that produces a bright microscopic signal when it selectively attaches to the gene or chromosome specific complementary DNA. The PathVysion HER-2 DNA Probe Kit contains two probes. One probe is directed to the HER-2 gene and the second DNA probe attaches itself to the chromosome 17 centromere. The signals appear as orange and green fluorescent dots for the HER-2 gene and chromosome 17, respectively. This enables a ratio of HER-2 to chromosome 17 signals to be calculated thereby correcting for aneuploidy of chromosome 17, which may not represent an amplified HER-2 state. Through this direct labeled FISH technology, the PathVysion HER-2 assay provides a highly accurate, reliable and reproducible means for assessing HER-2 status in breast cancer.

back to top

What is direct labeled FISH?
FISH has become a main-stream technology routinely used in diagnostic laboratories. Two kinds of FISH technology are commercially available - - direct labeled and indirect labeled.

Direct labeled FISH uses probes that have been pre-labeled with a specific fluorophore, allowing the fluorescent signal to be bound to the target in a single hybridization step. This method is more advanced, has fewer steps, is easier-to-read and has faster time-to-result. With PathVysion, HER-2 assessment is accomplished with a sequence specific DNA probe for the HER-2 gene and a second, separate DNA probe labeled in a different fluorophore for the repetitive sequences at the centromere of chromosome 17 (the HER-2 gene resides on chromosome 17). Direct FISH is Abbott Molecular's specialty.

Indirect labeled FISH involves probes prelabeled with a hapten, most commonly digoxigenin. After hybridization, fluorochrome-labeled antibodies to the hapten are used for probe detection. As an example, anti-digoxigenin, provides a "sandwiching" assay. Indirect FISH also requires additional blocking reagents, amplification steps, and has been reported to have a higher degree of background fluorescence problems.  The need for extra handling post-hybridization can cause disruptions in work-flow within a busy clinical laboratory; therefore, direct label FISH technology offers many advantages.

back to top

Why does the PathVysion HER-2 DNA kit include a probe for chromosome 17?
The HER-2 gene is located on chromosome 17. The cut-off between normal and abnormal is set by biology; more than one copy of the HER-2 gene per chromosome 17 is abnormal. Determination of the ratio of HER-2 gene copy number to chromosome 17 copy number is useful in the discrimination of aneusomy of chromosome 17 from true HER-2 gene amplification. In the case of aneusomy, more than the normal number of two copies of chromosome 17 are present in the cell and consequently, more than the normal number of two copies of the HER-2 gene are present. This result does not represent HER-2 amplification. Therefore a ratio of HER-2 to chromosome 17 is used in the cutoff of the PathVysion assay.

The chromosome 17 control probe also serves as a methodologic internal control for hybridization and controls for "nuclear truncation". When dealing with solid tumor tissue, nuclear truncation may occur. Most nuclei are roughly 10 microns thick, with a 4-6 micron section taken to be tested. The chromosome 17 probe is utilized to assess truncation and ensure the appropriate nuclei are evaluated in assessing HER-2 amplification.

back to top

What clinical trials have been conducted on the PathVysion HER-2 assay?
The pivotal clinical trial demonstrated that HER-2 amplification as determined by the PathVysion HER-2 DNA Probe could be used to identify those patients with a poor prognosis and furthermore, more likely to benefit from dose intensification of adriamycin-based therapies. The PathVysion HER-2 assay reliably detected HER-2 amplification, demonstrating a significant interaction between CAF (cyclophosphamide, doxorubicin, 5-fluorouracil) and amplified HER-23.

Herceptin package insert data from a retrospective analysis of 660 patients enrolled in the Herceptin clinical studies (all scoring 2+ or 3+ by the Clinical Trial IHC assay) demonstrate that the clinical benefits of Herceptin were greater in patients whose tumors tested FISH(+) than those that were FISH( - ). In the singlearm study of Herceptin as a single agent, the overall response rate in patients whose tumors tested as FISH(+) was 20%, while there were no responses in those who tested as FISH( - ).2

back to top

Why can it be beneficial to specifically request the PathVysion HER-2 DNA direct label FISH when assessing HER-2 status?
HER-2 status assessment is now considered the standard of care in the selection of therapy for invasive breast cancer, and some laboratories continue to use IHC to assess HER-2 status. PathVysion is the only method of HER-2 assessment that is FDA approved for use as an aid in determining prognostic factors in patients with stage II, node-positive breast cancer, as an aid to predict disease-free and overall survival in patients with stage II, node-positive breast cancer treated with adriamycin-based chemotherapy, and assisting in Herceptin (Trastuzumab) monoclonal antibody therapy selection.

back to top

Can the PathVysion HER-2 assay be performed in the average lab?
Yes. Most major reference labs, cancer centers and many local hospitals now perform the PathVysion HER-2 assay as their primary method of assessing HER-2 status. The protocol for the PathVysion HER-2 assay can be easily performed at any laboratory that currently performs IHC testing.

back to top

How do I explain the benefits of the PathVysion HER-2 assay to my patients?
Results of the PathVysion HER-2 asssay can be best explained to patients in terms of how they directly affect the therapy they are most likely to receive. When a breast cancer patient knows her HER-2 status, the appropriate therapy choices become clear.

back to top

Which patients should be tested with the PathVysion HER-2 assay?
Testing for HER-2 plays a key role in the management of invasive breast cancer. ASCO Guidelines and NCCN Practice guidelines recommend HER-2 testing for all patients with invasive breast cancer.  NCCN Practice guidelines indicate that patients should be tested by either IHC or FISH, but that all IHC 2+ results should be confirmed by FISH.2

back to top

Where can I obtain more information about the PathVysion HER-2 assay?
More information is currently available on PathVysion HER-2 from Abbott Molecular, Inc., including technical information, clinical trial data (package insert), a Patient Q&A brochure, a laboratory brochure. For more information, please contact Abbott Molecular today at 1-800-553-7042.

back to top

1 Press, et al. "Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.", Clinical Cancer Research 2005; 11(18) September 15, 2005.

2 Allison M, The HER2 testing conundrum. Nature Biotechnology 28 (2): 117-119, 2010.

3 PathVysion HER-2 DNA Probe Kit package insert.

4Sauter G, et al. Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations. J Clin Oncol 27:1323-1333, 2009.

5Dressler L, et al. Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy i Node-Positive Breast Cancer Patients. J Clin Oncol. 23:4287-4297, 2005

Intended Use
The PathVysion HER-2 DNA Probe Kit (PathVysion Kit) is designed to detect amplification of the HER-2/neu gene via fluorescence in situ hybridization (FISH) in formalin-fixed, paraffin-embedded human breast cancer tissue specimens. Results from the PathVysion Kit are intended for use as an adjunct to existing clinical and pathologic information currently used as prognostic factors in stage II, node-positive breast cancer patients. The PathVysion Kit is further indicated as an aid to predict disease-free and overall survival in patients with stage II, node-positive breast cancer treated with adjuvant cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) chemotherapy.

The PathVysion Kit is indicated as an aid in the assessment of patients for whom HERCEPTIN (Trastuzumab) treatment is being considered (see HERCEPTIN package insert).

Warning:

HERCEPTIN therapy selection
NOTE: All of the patients in the HERCEPTIN clinical trials were selected using an investigational immunohistochemical assay (CTA). None of the patients in those trials were selected using the PathVysion assay. The PathVysion assay was compared to the CTA on a subset of clinical trial samples and found to provide acceptably concordant results. The actual correlation of the PathVysion assay to HERCEPTIN clinical outcome in prospective clinical trials has not been established.
Adjuvant therapy selection
The PathVysion Kit is not intended for use to screen for or diagnose breast cancer. It is intended to be used as an adjunct to other prognostic factors currently used to predict disease-free and overall survival in stage II, node-positive breast cancer patients and no treatment decision for stage II, node-positive breast cancer patients should be based on HER-2/neu gene amplification status alone. Selected patients with breast cancers shown to lack amplification of HER-2/neu may still benefit from CAF (cyclophosphamide, doxorubicin, 5-fluorouracil) adjuvant therapy on the basis of other prognostic factors that predict poor outcome (e.g. tumor size, number of involved lymph nodes, and hormone receptor status). Conversely, selected patients with breast cancers shown to contain gene amplification may not be candidates for CAF therapy due to preexisting or intercurrent medical illnesses.
Required Training
Abbott Molecular will provide training in specimen preparation, assay procedure, and interpretation of FISH testing of the Her-2 gene for inexperienced users. It is also recommended that a laboratory that has previously received training but now has new personnel performing the assay request training for the new users.

Limitations
  • The PathVysion Kit has been optimized only for identifying and quantifying chromosome 17 and the HER-2/neu gene in interphase nuclei from formalin-fixed, paraffin-embedded human breast tissue specimens. Other types of specimens or fixatives should not be used.
  • The performance of the PathVysion Kit was validated using the procedures provided in the package insert only. Modifications to these procedures may alter the performance of the assay.
  • Performance characteristics of the PathVysion Kit have been established only for node positive patients receiving the designated regimens of CAF and for metastatic breast cancer patients being considered for HERCEPTIN therapy. Performance with other treatment regimens has not been established.
  • The clinical interpretation of any test results should be evaluated within the context of the patient's medical history and other diagnostic laboratory test results.
  • FISH assay results may not be informative if the specimen quality and/or specimen slide preparation is inadequate. Technologists performing the FISH signal enumeration must be capable of visually distinguishing between the orange and green signals.


CAUTION: United States Federal law restricts this device to sale and distribution to or on the order of a physician or to a clinical laboratory; use is restricted to, by, or on the order of a physician.

For In Vitro Diagnostic Use